Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Momentum
Price
Very Weak
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.3.9629.5566
Address
Level 15 500 Collins Street Melbourne, Victoria (VIC) 3000
Description
Paradigm Biopharmaceuticals Ltd. is a biopharmaceutical company engaged in researching and developing therapeutic products for human use. It is a drug repurposing company which seeks to find new uses for old drugs. The company was founded by Paul John Rennie on May 2, 2014 and is headquartered in Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.17 - 0.61
Trade Value (12mth)
AU$105,387.00
1 week
7.92%
1 month
19.78%
YTD
36.25%
1 year
51.39%
All time high
4.35
EPS 3 yr Growth
23.80%
EBITDA Margin
%
Operating Cashflow
-$66m
Free Cash Flow Return
-169.40%
ROIC
-150.70%
Interest Coverage
-4,477.80
Quick Ratio
7.20
Shares on Issue (Fully Dilluted)
350m
HALO Sector
Healthcare
Next Company Report Date
29-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.30
Date | Announcements |
---|---|
14 February 25 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
14 February 25 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
11 February 25 |
Application for quotation of securities - PAR
×
Application for quotation of securities - PAR |
11 February 25 |
Listing of Options - Top 20 Holders and Distribution Reports
×
Listing of Options - Top 20 Holders and Distribution Reports |
03 February 25 |
Cancel - Proposed issue of securities - PAR
×
Cancel - Proposed issue of securities - PAR |
03 February 25 |
Proposed issue of securities - PAR
×
Proposed issue of securities - PAR |
31 January 25 |
PAR Selects Advanced Clinical as CRO for Phase 3
×
PAR Selects Advanced Clinical as CRO for Phase 3 |
31 January 25 |
Loyalty and Piggyback Options Program
×
Loyalty and Piggyback Options Program |
31 January 25 |
Proposed issue of securities - PAR
×
Proposed issue of securities - PAR |
30 January 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
29 January 25 |
Application for quotation of securities - PAR
×
Application for quotation of securities - PAR |
24 January 25 |
Paradigm Receives $6.3m R&D Tax Refund
×
Paradigm Receives $6.3m R&D Tax Refund |
16 January 25 |
Notice of release of escrowed securities
×
Notice of release of escrowed securities |
30 December 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
20 December 24 |
Notification regarding unquoted securities - PAR
×
Notification regarding unquoted securities - PAR |
13 December 24 |
Application for quotation of securities - PAR
×
Application for quotation of securities - PAR |
13 December 24 |
Cleansing Notice
×
Cleansing Notice |
09 December 24 |
Successful Completion of $16M Placement for Phase 3
×
Successful Completion of $16M Placement for Phase 3 |
09 December 24 |
Proposed issue of securities - PAR
×
Proposed issue of securities - PAR |
09 December 24 |
PAR Capital Raising Presentation
×
PAR Capital Raising Presentation |
05 December 24 |
Appendix 3H - Notification of cessation of securities
×
Appendix 3H - Notification of cessation of securities |
05 December 24 |
Trading Halt
×
Trading Halt |
05 December 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
05 December 24 |
Change of Director's Interest Notice
×
Change of Director's Interest Notice |
04 December 24 |
Appendix 2A
×
Appendix 2A |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.